Frazier Healthcare Partners to Buy MatrixCare from ResMed
Private equity firm Frazier Healthcare Partners is acquiring MatrixCare, a long-term care software platform, from medical device maker ResMed.
Frazier Healthcare Partners, a private equity firm focused on the healthcare sector, has agreed to acquire MatrixCare from ResMed, the sleep and respiratory health company best known for its medical devices. The deal signals a strategic pivot for ResMed, which is shedding a software asset to sharpen its focus on its core hardware and connected-care business.
MatrixCare is a leading provider of electronic health record and management software tailored to long-term and post-acute care facilities, including skilled nursing, senior living, and home health organizations. Its client base sits at the intersection of an aging population and accelerating digital adoption in care settings — a combination that makes it an attractive standalone asset for a dedicated healthcare investor.
Read more Vanguard Seeks Digital Assets Leader in Crypto Strategy Shift →
For Frazier Healthcare Partners, the acquisition fits a well-established playbook of backing healthcare technology and services companies with durable market positions. Long-term care software is a sector with strong retention dynamics, as switching costs for facilities that have embedded an EHR platform into clinical and billing workflows are notably high — a characteristic that tends to support stable recurring revenue.
From ResMed's perspective, divesting MatrixCare allows the company to redeploy capital toward its device and digital health ecosystem, where it competes in the high-growth sleep apnea and respiratory care markets. The move reflects a broader industry pattern of large medtech companies reassessing whether software subsidiaries are best developed independently or under specialized ownership.
The transaction underscores sustained investor appetite for healthcare IT assets even amid tighter deal markets, as the operational demands of an aging U.S. population continue to drive demand for purpose-built clinical software. Continue reading at SeekingAlpha.
